Basic Information
RNALocate ID: | RLID:11003994 |
RNA Symbol: | hsa-miR-502-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-502-3p |
RNA ID: | miRBase:MIMAT0004775 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23539611 |
Tissue/Cell Line: | Seminal plasma |
Method: | Microarray |
Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002670 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01002671 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:11003989 | Exosome | B cell line (Raji)|Primary dendritic cells | 21505438 |
RLID:11003990 | Exosome | Plasma | 23663360 |
RLID:11003991 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11003992 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11003993 | Microvesicle | Plasma | 23077538 |
RLID-D:11000207 | Exosome | Blood | |
RLID-D:11000687 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-502-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-55601 |
MNDR | hsa-miR-502-3p | Ovarian clear cell carcinoma | MNDR-E-MI-55602 |
MNDR | hsa-miR-502-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-55603 |
MNDR | hsa-miR-502-3p | Lymphoma | MNDR-E-MI-55604 |
MNDR | hsa-miR-502-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-55605 |
MNDR | hsa-miR-502-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-55606 |
MNDR | hsa-miR-502-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-55607 |
MNDR | hsa-miR-502-3p | Her2-receptor positive breast cancer | MNDR-E-MI-55608 |
MNDR | hsa-miR-502-3p | Chronic lymphocytic leukemia | MNDR-E-MI-55609 |
MNDR | hsa-miR-502-3p | Gastric cancer | MNDR-E-MI-55610 |
MNDR | hsa-miR-502-3p | Alzheimer disease | MNDR-E-MI-55611 |
MNDR | hsa-miR-502-3p | Bladder cancer | MNDR-E-MI-55612 |
MNDR | hsa-miR-502-3p | Esophageal carcinoma | MNDR-E-MI-55613 |
MNDR | hsa-miR-502-3p | Dysautonomia familial | MNDR-E-MI-55614 |
MNDR | hsa-miR-502-3p | Seizures | MNDR-E-MI-55615 |
MNDR | hsa-miR-502-3p | Cardiovascular disease | MNDR-E-MI-55616 |
MNDR | hsa-miR-502-3p | Lung cancer | MNDR-E-MI-55617 |
MNDR | hsa-miR-502-3p | Parkinson disease | MNDR-E-MI-55618 |
MNDR | hsa-miR-502-3p | Breast cancer | MNDR-E-MI-55619 |
MNDR | hsa-miR-502-3p | Pancreatic cancer | MNDR-E-MI-55620 |
MNDR | hsa-miR-502-3p | Nephroblastoma | MNDR-E-MI-55621 |
MNDR | hsa-miR-502-3p | Colon cancer | MNDR-E-MI-55622 |
MNDR | hsa-miR-502-3p | Familial ovarian cancer | MNDR-E-MI-55623 |
MNDR | hsa-miR-502-3p | Kidney cancer | MNDR-E-MI-55624 |
MNDR | hsa-miR-502-3p | Glioblastoma | MNDR-E-MI-55625 |
MNDR | hsa-miR-502-3p | Astrocytoma | MNDR-E-MI-55626 |
MNDR | hsa-miR-502-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-55627 |
MNDR | hsa-miR-502-3p | Gastric adenocarcinoma | MNDR-E-MI-55628 |
MNDR | hsa-miR-502-3p | Cervical squamous cell carcinoma | MNDR-E-MI-55629 |
MNDR | hsa-miR-502-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-55630 |
MNDR | hsa-miR-502-3p | Lung squamous cell carcinoma | MNDR-E-MI-55631 |
MNDR | hsa-miR-502-3p | Lung adenocarcinoma | MNDR-E-MI-55632 |
MNDR | hsa-miR-502-3p | Adrenocortical carcinoma | MNDR-E-MI-55633 |
MNDR | hsa-miR-502-3p | Thyroid carcinoma | MNDR-E-MI-55634 |
MNDR | hsa-miR-502-3p | Ovarian carcinoma | MNDR-E-MI-55635 |
MNDR | hsa-miR-502-3p | Bladder urothelial carcinoma | MNDR-E-MI-55636 |
MNDR | hsa-miR-502-3p | Pancreatic adenocarcinoma | MNDR-E-MI-55637 |
MNDR | hsa-miR-502-3p | Carcinoma renal cell | MNDR-E-MI-55638 |
MNDR | hsa-miR-502-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-55639 |
MNDR | hsa-miR-502-3p | Renal clear cell carcinoma | MNDR-E-MI-55640 |
MNDR | hsa-miR-502-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-55641 |
MNDR | hsa-miR-502-3p | Hepatocellular carcinoma | MNDR-E-MI-55642 |
MNDR | hsa-miR-502-3p | Familiar ovarian carcinoma | MNDR-E-MI-55643 |
MNDR | hsa-miR-502-3p | B-cell lymphoma | MNDR-E-MI-55644 |
MNDR | hsa-miR-502-3p | Rheumatoid arthritis | MNDR-E-MI-55645 |
MNDR | hsa-miR-502-3p | Retinoblastoma | MNDR-E-MI-55646 |
MNDR | hsa-miR-502-3p | Hodgkin lymphoma | MNDR-E-MI-55647 |
MNDR | hsa-miR-502-3p | Crohn disease | MNDR-E-MI-55648 |
MNDR | hsa-miR-502-3p | Neuromyelitis optica | MNDR-E-MI-55649 |
MNDR | hsa-miR-502-3p | Colorectal cancer | MNDR-E-MI-55650 |
MNDR | hsa-miR-502-3p | Nasopharynx carcinoma | MNDR-E-MI-55651 |
MNDR | hsa-miR-502-3p | Ependymoma | MNDR-E-MI-55652 |
MNDR | hsa-miR-502-3p | Nasopharyngeal cancer | MNDR-E-MI-55653 |
MNDR | hsa-miR-502-3p | Hypersomnolence idiopathic | MNDR-E-MI-55654 |
MNDR | hsa-miR-502-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-55655 |
MNDR | hsa-miR-502-3p | Stroke lacunar | MNDR-E-MI-55656 |
MNDR | hsa-miR-502-3p | Breast cancer her3+ negative | MNDR-E-MI-55657 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | B4GALT5 | Homo sapiens | RR00208370 |
TOP